|
業務類別
|
Biotechnology |
|
業務概覽
|
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")). |
| 公司地址
| 302 East Pettigrew Street, Dibrell Building, Suite A-100, Durham, NC, USA, 27701 |
| 電話號碼
| +1 919 314-5512 |
| 傳真號碼
| +1 480 393-5553 |
| 公司網頁
| https://www.precisionbiosciences.com |
| 員工數量
| 68 |
| Mr. John Alexander Kelly |
Chief Financial Officer and Principal Accounting Officer |
美元 472.53K |
08/04/2026 |
| Mr. Michael Amoroso |
Director, President and Chief Executive Officer |
美元 650.88K |
08/04/2026 |
| Mr. Dario Scimeca |
General Counsel and Secretary |
美元 445.88K |
08/04/2026 |
| Mr. Jeff Smith, PhD |
Chief Research Officer |
-- |
08/04/2026 |
|
|
| Mr. Geno J. Germano |
Independent Director |
08/04/2026 |
| Dr. Stanley R. Frankel, M.D. |
Independent Director |
08/04/2026 |
| Mr. Michael Amoroso |
Director, President and Chief Executive Officer |
08/04/2026 |
| Ms. Melinda Brown |
Independent Director |
08/04/2026 |
| Mr. Kevin J. Buehler |
Chairman of the Board |
08/04/2026 |
| Ms. Shari Lisa Pire, J.D. |
Independent Director |
08/04/2026 |
|
|
|
|
